Growth was driven by expansion across key business segments, improving efficiencies, and sustained demand across institutional and retail channels
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
Antiviral injection addressing CMV and HSV infections had US market sales of nearly $15 million in the last 12 months
Ex-US revenue rose sharply by 21% YoY to Rs. 2, 240.4 crore ($254 million); Operational PAT grew 50.3% YoY to Rs. 518.1 crore
The certification follows an inspection conducted by the Malta Medicines Authority between January 29, 2026, and February 3, 2026
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
Approval strengthens the company’s growing international anti-infective portfolio
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
